Full text loading...
Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy
1.D. J. Macey, S. J. Denardo, G. L. Denardo, J. K. Goodnight, and M. W. Unger, “Uptake of indium-111 labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma,” Am. J. Physiol. Imag. 3, 1–6 (1988).
2.S. E. Order, J. L. Klein, D. Ettinger, P. Alderson, S. Siegelman, and P. Leichner, “Phase I–II study of radiolabelled antibody integrated in the treatment of primary hepatic malignancies,” Int. J. Radiat. Oncol., Biol., Phys. 6, 703–710 (1980).
3.H. B. Breitz, P. L. Weiden, J.-L. Vanderheyden, J. W. Applebaum, M. J. Bjorn, M. F. Fer, S. B. Wolf, B. A. Ratliff, C. A. Seiler, D. C. Foisie, D. R. Fisher, R. W. Schroff, A. R. Fritzberg, and P. G. Abrams, “Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials,” J. Nucl. Med. 33, 1099–1112 (1992).
4.D. M. Goldenberg, J. Horowitz, R. M. Sharkey, T. C. Hall, S. Murthy, H. Goldenberg, R. E. Lee, R. Stein, J. A. Siegal, D. O. Izon, K. Burger, L. C. Swayne, E. Belisle, H. J. Hansen, and C. M. Pinsky, “Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody,” J. Clin. Oncol. 9, 548–564 (1991).
5.J. F. Fowler, “Radiobiological aspects of low dose rates in radioimmunotherapy,” Int. J. Radiat. Oncol., Biol., Phys. 18, 1261–1269 (1990).
6.V. K. Langmuir, J. F. Fowler, S. J. Knox, B. W. Wessels, R. M. Sutherland, and J. Y. C. Wong, “Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry,” Med. Phys. 20, Pt. 2, 601–610 (1993).
7.D. V. Rao, and R. W. Howell, “Time dose fractionation in radioimmunotherapy: Implications for selecting radionuclides,” J. Nucl. Med. 34, 1801–1810 (1993).
8.R. W. Howell, S. M. Goddu, and D. V. Rao, “Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides,” J. Nucl. Med. 35, 1861–1869 (1994).
9.G. W. Barendsen, “Dose fractionation, dose rate and iso-effect relationships for normal tissue responses,” Int. J. Radiat. Oncol., Biol., Phys. 8, 1981–1997 (1982).
10.R. G. Dale, “The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy,” Br. J. Radiol. 58, 515–528 (1985).
11.J. F. Fowler, “The linear-quadratic formula and progress in fractionated radiotherapy,” Br. J. Radiol. 62, 679–694 (1989).
12.R. W. Howell, S. M. Goddu, and D. V. Rao, “Design and performance characteristics of an experimental Cs-137 irradiator to simulate internal radionuclide dose rate patterns,” J. Nucl. Med. 38, 727–731 (1997).
13.D. V. Rao, and R. W. Howell, “On the modeling of the tumor uptake to determine the time-dose-fractionation (TDF) effect in radioimmunotherapy (reply to letter),” J. Nucl. Med. 35, 1562–1564 (1994).
14.A. Liu, L. E. Williams, A. J. Demidecki, A. A. Raubitschek, and J. Y. C. Wong, “On the modeling of the tumor uptake to determine the time-dose-fractionation (TDF) effect in radioimmunotherapy (letter),” J. Nucl. Med. 35, 1561–1562 (1994).
15.R. G. Dale, “Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model,” Br. J. Radiol. 62, 241–244 (1989).
16.C. C. Ling, “Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model,” Int. J. Radiat. Oncol., Biol., Phys. 23, 81–87 (1992).
17.B. W. Wessels, and R. D. Rogus, “Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies,” Med. Phys. 11, 638–645 (1984).
18.C.-T. Wu, and L. G. Lajtha, “Haemopoietic stem-cell kinetics during continuous irradiation,” Int. J. Radiat. Biol. 27, 41–50 (1975).
19.J. Y. C. Wong, L. E. Williams, A. J. Demidecki, B. W. Wessels, and X. W. Yan, “Radiobiologic studies comparing yttrium-90 irradiation and external beam irradiation in vitro,” Int. J. Radiat. Oncol., Biol., Phys. 20, 715–722 (1991).
20.J. L. Humm, and L. M. Cobb, “Nonuniformity of tumor dose in radioimmunotherapy,” J. Nucl. Med. 31, 75–83 (1990).
21.C. S. Kwok, W. V. Prestwich, and B. C. Wilson, “Calculation of radiation doses for nonuniformly distributed beta and gamma radionuclides in soft tissue,” Med. Phys. 12, 405–412 (1985).
22.R. W. Howell, D. V. Rao, and K. S. R. Sastry, “Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors,” Med. Phys. 16, 66–74 (1989).
23.R. G. Dale, B. J. Jones, and I. P. Coles, “The effect of tumour shrinkage on biological effectiveness of permanent brachytherapy implants,” Br. J. Radiol. 67, 639–645 (1994).
24.K. E. Britton, S. J. Mather, and M. Granowska, “Radiolabeled monoclonal antibodies in oncology. III. Radioimmunotherapy,” Nucl. Med. Commun. 12, 333–347 (1991).
25.S. Shen, G. L. DeNardo, S. J. DeNardo, Q. Salako, G. Morris, D. Banks, A. Yuan, and D. A. DeNardo, “Dosimetric evaluation of copper-64 in copper-67- 2IT-BAT-Lym-1 for radioimmunotherapy,” J. Nucl. Med. 37, 146–150 (1996).
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Article metrics loading...